ArticleAIDS (London, England)2008
Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.
Article in AIDS (London, England), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- Antiretroviral therapy response among HIV-2 infected patients: a systematic review.BMC infectious diseases · 2014Pooled it
- First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Trial
- The HIV-2 OGH double reporter virus shows that HIV-2 is less cytotoxic and less sensitive to reactivation from latency than HIV-1 in cell culture.Journal of virus eradication · 2023Article
- HIV-2 Neutralization Sensitivity in Relation to Co-Receptor Entry Pathways and Env Motifs.International journal of molecular sciences · 2022Article
- Article
- Human Immunodeficiency Virus Type 2: The Neglected Threat.Pathogens (Basel, Switzerland) · 2021Review
- Evolution toward beta common chain receptor usage links the matrix proteins of HIV-1 and its ancestors to human erythropoietin.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution.Virus evolution · 2021Article
- HIV-1/2 differentiation in a South African public laboratory.Southern African journal of HIV medicine · 2021Article
- HIV-2 as a model to identify a functional HIV cure.AIDS research and therapy · 2019Review
- Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR6 co-receptor expression in attenuated HIV-2 infection.PLoS pathogens · 2019Article
- HIV-2 infection is associated with preserved GALT homeostasis and epithelial integrity despite ongoing mucosal viral replication.Mucosal immunology · 2018Article
- Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection.Journal of virus eradication · 2017Article
- Effect of sex and age on outcomes among HIV-2-infected patients starting antiretroviral therapy in West Africa.AIDS (London, England) · 2016Article
- Mortality and survival patterns of people living with HIV-2.Current opinion in HIV and AIDS · 2016Review
- Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort.Journal of the International AIDS Society · 2016Article
- Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the IeDEA West Africa Collaboration.PloS one · 2015Article
- Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response.Retrovirology · 2013Article
- The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?Retrovirology · 2013Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHIV-2 is known to be less pathogenic than HIV-1, although the underlying mechanisms are still debated. We compared the changes over time in viro-immunological markers in HIV-1 and HIV-2-infected patients living in France during natural history and after initiation of the first combination antiretroviral therapy (CART).
methodPatients were included in the ANRS CO3 HIV-1 cohort (N = 6707) or the ANRS CO5 HIV-2 cohort (N = 572). HIV-1-infected patients were matched to HIV-2 patients according to sex, age, HIV transmission group and period of treatment initiation. Changes in markers were estimated using linear mixed models.
resultsAnalyses were performed for three groups of patients: those with estimated date of contamination (98 HIV-1 and 49 HIV-2-seroincident patients); untreated seroprevalent patients (320 HIV-1 and 160 HIV-2); and those initiating a first CART (59 HIV-1 and 63 HIV-2). In group 1, CD4 T-cell counts decreased less rapidly in HIV-2 than HIV-1 patients (-9 versus -49 cells/microl per year, P < 10(-4)). Results were similar in group 2. Baseline CD4 cell count at CART initiation was not different according to the type of infection. During the first 2 months of treatment, the CD4 cell count increased by +59 cells/microl per month (CI 34; 84) for HIV-1 and +24 (CI 6; 42) for HIV-2. The plasma viral load drop was threefold more important in HIV-1 patients: -1.56 log10/ml per month versus -0.62 among HIV-2 patients (P < 10(-4)).
conclusionDifferences between the two infections during natural history are similar to those previously described in Africa. Once treatment is started, response is poorer in HIV-2 than in HIV-1 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.